Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy - Concepedia

Concepedia

Publication | Open Access

Radiomics model based on intratumoral and peritumoral features for predicting major pathological response in non-small cell lung cancer receiving neoadjuvant immunochemotherapy

DOI Full Paper Access

17

Citations

25

References

2024

Year

Dingpin Huang, Lin Chen, Yangyang Jiang, Enhui Xin, Fangyi Xu, Yi Gan, Rui Xu, Fang Wang, Haiping Zhang, Kaihua Lou,

Frontiers in Oncology

Abstract

We established a CRC model that incorporates intratumoral and peritumoral features and histopathological type, providing an effective approach for selecting NSCLC patients suitable for neoadjuvant immunochemotherapy.

References

	Year	Citations
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, CA A Cancer Journal for Clinicians	2021	109.5K
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial Mariano Provencio, Ernest Nadal, Amelia Insa, The Lancet Oncology MedicineImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation Oncology	2020	788
Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy Roberto Ferrara, Laura Mezquita, Matthieu Texier, JAMA Oncology	2018	719
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial Catherine A. Shu, Justin F. Gainor, Mark M. Awad, The Lancet Oncology OncologyMetronomic TherapyPathologyBronchial NeoplasmCancer Treatment	2020	621
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Journal of Clinical Oncology	2021	614
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet, Journal of Clinical Oncology	2021	336
Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas Niha Beig, Mohammadhadi Khorrami, Mehdi Alilou, Radiology	2018	318
Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer Mohammadhadi Khorrami, Prateek Prasanna, Amit Gupta, Cancer Immunology Research	2019	303
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer Chun‐Gon Kim, Kyoung‐Ho Kim, Kyoung‐Ho Pyo, Annals of Oncology Pd-1/pd-l1 BlockadeNon-small-cell Lung CancerAdvanced Lung DiseaseMedicineImmunology	2019	296
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Journal of Thoracic Oncology	2021	286

Page 1